These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 7044404)

  • 1. Corynebacterium parvum and metastatic breast cancer.
    Haskell CM; Sarna GP; Liu PY
    Br J Cancer; 1982 May; 45(5):794-5. PubMed ID: 7044404
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy and corynebacterium parvum for induction and maintenance of remission in acute myelogenous leukaemia--a controlled study.
    Shetty PA; Pai VR; Jani PH; Antia PK; Shahane AD
    Indian J Cancer; 1983; 20(2):119-23. PubMed ID: 6580265
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.
    Leahy BC; Honeybourne D; Brear SG; Carroll KB; Thatcher N; Stretton TB
    Eur J Respir Dis; 1985 Jan; 66(1):50-4. PubMed ID: 3979476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The use of Corynebacterium parvum in pleurodesis].
    Helin T; Haahtela T
    Duodecim; 1988; 104(4):262-5. PubMed ID: 3168834
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I study of corynebacterium parvum in patients with solid tumors.
    Band PR; Jao-King C; Urtasun RC; Haraphongse M
    Cancer Chemother Rep; 1975; 59(6):1139-45. PubMed ID: 769953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of cancer with corynebacterium parvum.
    Halpern B
    Ann Allergy; 1978 Mar; 40(3):155-7. PubMed ID: 637374
    [No Abstract]   [Full Text] [Related]  

  • 7. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
    Yadeau R; Bates HA; Fortuny I
    Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
    [No Abstract]   [Full Text] [Related]  

  • 8. Intrapleural and intravenous Corynebacterium parvum in patients with resected stage I and II non-small cell carcinoma of the lung. The Ludwig Lung Cancer Study Group.
    Ludwig Lung Cancer Study Group
    Cancer Immunol Immunother; 1986; 23(1):1-4. PubMed ID: 2876772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
    Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
    Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
    [No Abstract]   [Full Text] [Related]  

  • 10. Hypercoagulability after immunotherapy with Corynebacterium parvum in man.
    Harenberg J; Baumgärtner A; Fritze D; Zimmermann R
    Blut; 1982 Apr; 44(4):241-7. PubMed ID: 7082858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma.
    Mitcheson HD; Priestman TJ
    Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635
    [No Abstract]   [Full Text] [Related]  

  • 12. Surgery plus Corynebacterium parvum immunotherapy for Lewis lung carcinoma in mice.
    Karrer K; Rella W; Goldin A
    Eur J Cancer (1965); 1979 Jun; 15(6):867-73. PubMed ID: 499275
    [No Abstract]   [Full Text] [Related]  

  • 13. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum.
    Hamilton DN; Bell PR
    Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648
    [No Abstract]   [Full Text] [Related]  

  • 14. [Preliminary results of studies of the effect of immunostimulation combined with chemotherapy in patients with ovarian cancer].
    Pawlicki M; Majsak T
    Ginekol Pol; 1988 Jun; 59(6):358-62. PubMed ID: 3069616
    [No Abstract]   [Full Text] [Related]  

  • 15. Coagulation and fibrinolysis during the infusion of Corynebacterium parvum in man.
    Cederholm-Williams SA; King A; Allington MJ; Gill PG; Sharp AA; Britton BJ
    Br J Cancer; 1978 Jun; 37(6):1074-7. PubMed ID: 678428
    [No Abstract]   [Full Text] [Related]  

  • 16. [Comparison of the effectiveness and adverse effects of a Corynebacterium parvum vaccine made in Czechoslovakia with Coparvax, a British preparation made by Wellcome, in the treatment of malignant pleural effusions].
    Marel M; Melínová L; Bednár M
    Cas Lek Cesk; 1989 Aug; 128(34):1071-4. PubMed ID: 2790915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Letter: Immunological control of cancer.
    Israel L; Edelstein R
    Lancet; 1975 Apr; 1(7913):979-10. PubMed ID: 48154
    [No Abstract]   [Full Text] [Related]  

  • 18. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
    Karakousis CP; Didolkar MS; Han T
    Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
    [No Abstract]   [Full Text] [Related]  

  • 19. [Immunotherapy with Corynebacterium parvum in experimental influenza virus infections and mixed infections in mice].
    Denys A; Kowalska M; Szydłowska T; Białek J
    Pol Tyg Lek; 1986 May; 41(19):619-23. PubMed ID: 3763446
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
    Hortobagyi GN; Yap HY; Wiseman CL; Blumenschein GR; Buzdar AU; Legha SS; Gutterman JU; Hersh EM; Bodey GP
    Cancer Treat Rep; 1980 Jan; 64(1):157-9. PubMed ID: 6991103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.